From Elsevier Business Intelligence
Including company and deal data plus articles from publications like IN VIVO, Start-Up, The RPM Report, and Medtech Insight.

MAP Pharmaceuticals Inc.

www.mappharma.com

Most Recent Related Deals

MAP gets equity commitment of up to $60mm from Azimuth, 11/2009
MAP Pharmaceuticals nets $31.9mm through follow-on offering, 8/2009
AZ gets rights to MAP's unit dose budesonide; terminated, 12/2008
MAP Pharmaceuticals nets $64.2mm in initial public offering, 10/2007
Fourth financing round gives MAP Pharmaceuticals $50mm, 3/2007
MAP Pharmaceuticals gets $25.25mm with Series C round, 1/2006
Eiffel and MAP develop inhaled drug-device combinations, 9/2005
MAP gets expanded use of Elan's NanoCrystal, 7/2005
Eiffel signs asthma deal with MAP, 11/2004
MAP Pharmaceuticals brings in $30mm with Series B round, 9/2004

Most Recent Related Articles

Click an article to see a free preview (11 of 7).

Dealmaking When Pharma's the Only Game in Town, Start-Up 9/2009
What Happens After the Device IPO?, In Vivo 6/2009
Start-Up Quarterly Statistics, Q4 2008, In Vivo 2/2009
Start-Up Quarterly Statistics, Q4 2007, Start-Up 2/2008
Start-Up Quarterly Statistics, Q4 2007, In Vivo 2/2008
MAP Pharmaceuticals Inc., Start-Up 11/2004
MAP Pharmaceuticals Inc., In Vivo 11/2004
Start-Up Previews (11/04), Start-Up 11/2004
Start-Up Previews (11/04), IN VIVO 11/2004
Drug Delivery's Product Risk and Reward, Start-Up 10/2004
Drug Delivery's Product Risk and Reward, In Vivo 10/2004

Copyright © 2009 Elsevier Inc. All rights reserved. Elsevier Business Intelligence, www.ElsevierBI.com.
Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com.